Connection

Co-Authors

This is a "connection" page, showing publications co-authored by PADMANEE SHARMA and SANGEETA GOSWAMI.
Connection Strength

9.258
  1. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024 Dec; 25(12):2186-2199.
    View in: PubMed
    Score: 0.995
  2. Loss of ARID1A 'loops' in STING. Trends Immunol. 2024 Aug; 45(8):568-570.
    View in: PubMed
    Score: 0.972
  3. Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nat Cancer. 2023 Oct; 4(10):1455-1473.
    View in: PubMed
    Score: 0.913
  4. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023 02; 23(2):106-120.
    View in: PubMed
    Score: 0.839
  5. A composite T?cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell. 2022 03 14; 40(3):249-251.
    View in: PubMed
    Score: 0.825
  6. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020 06 17; 12(548).
    View in: PubMed
    Score: 0.731
  7. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
    View in: PubMed
    Score: 0.707
  8. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
    View in: PubMed
    Score: 0.642
  9. A potential biomarker for anti-PD-1 immunotherapy. Nat Med. 2018 02 07; 24(2):123-124.
    View in: PubMed
    Score: 0.621
  10. Genetic biomarker for cancer immunotherapy. Science. 2017 07 28; 357(6349):358.
    View in: PubMed
    Score: 0.599
  11. Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma. Res Sq. 2024 Nov 12.
    View in: PubMed
    Score: 0.248
  12. TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Nat Commun. 2024 Jul 10; 15(1):5291.
    View in: PubMed
    Score: 0.242
  13. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
    View in: PubMed
    Score: 0.222
  14. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 04; 11(4):838-857.
    View in: PubMed
    Score: 0.193
  15. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.187
  16. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
    View in: PubMed
    Score: 0.173
  17. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
    View in: PubMed
    Score: 0.052
  18. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.049
  19. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.